Exocrine Pancreas Carcinoma

In pancreatic cancer cell lines MiaPaCa2 and Panc1, gemcitabine 1 μmol/L induced NR4A2/NURR1 expression and triggered cytoprotective autophagy, while both CRISPR-mediated NR4A2 knockout and the NR4A2 … (full text at CIViC)

PMID 35582016 · Zarei et al., 2021 · Open in CIViC

In a retrospective TCGA PDAC (tumors n = 179, normals n = 171), high ATG7 expression was significantly associated with poorer survival on Kaplan–Meier analysis (P = 0.013), and high ATG12 expression s… (full text at CIViC)

PMID 35582016 · Zarei et al., 2021 · Open in CIViC

A patient with pancreatic ductal adenocarcinoma (PDAC) and a somatic PALB2 mutation (NM_024675.4: c.3350+1G>T) experienced disease progression after 10 cycles of FOFIRINOX and 2 cycles of gemcitabine.… (full text at CIViC)

PMID 36119518 · Kachmazov et al., 2022 · Open in CIViC

In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depl… (full text at CIViC)

PMID 11792751 · Plath et al., 2002 · Open in CIViC

Surgically resected PDACs were used to create tissue microarrays, which were scored for antibody staining of hENT1 (SLC29A1). For patients treated with gemcitabine (n=243), high levels of hENT1 were a… (full text at CIViC)

PMID 22705007 · Maréchal et al., 2012 · Open in CIViC

In this case report of a single patient with pancreatic adenocarcinoma was found to harbour a SLC4A4::ROS1 fusion by NGS analysis. Based on the presence of the ROS1 fusion the patient was initiated on… (full text at CIViC)

PMID 37079858 · Reutter et al., 2023 · Open in CIViC

In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was ass… (full text at CIViC)

PMID 11751510 · Tascilar et al., 2001 · Open in CIViC

In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients.

PMID 19584151 · Blackford et al., 2009 · Open in CIViC

In a preclinical study using STK11/LKB1-deficient pancreatic ductal adenocarcinoma (PDAC) cell lines (TB 32047, PANC-1, SUIT2, SU86.86, KPC792) and C57BL/6 orthotopic mouse models (n = 5 per group), t… (full text at CIViC)

PMID 38461159 · Zhang et al., 2024 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC